CXC型趨化因子及其受體軸在慢性阻塞性肺疾病中的研究進展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

楊罡 ^1,2 , 趙峻 ^1,2 ,  張云輝 ²

1. ;
2. ;

Corresponding?author：

張云輝, Email: yunhuizhang3188@126.com

Keywords：

DOI：

10.7507/1671-6205.202102043

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 楊罡, 趙峻, 張云輝. CXC型趨化因子及其受體軸在慢性阻塞性肺疾病中的研究進展. Chinese Journal of Respiratory and Critical Care Medicine, 2021, 20(10): 748-752. doi: 10.7507/1671-6205.202102043 Copy

1.	Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health study): a national cross-sectional study. Lancet, 2018, 391(10131): 1706-1717.
2.	Henrot P, Prevel R, Berger P, et al. Chemokines in COPD: from implication to therapeutic Use. Int J Mol Sci, 2019, 20(11): 2785.
3.	Barnes PJ. Inflammatory endotypes in COPD. Allergy, 2019, 74(7): 1249-1256.
4.	Hughes CE, Nibbs RJB. A guide to chemokines and their receptors. FEBS J, 2018, 285(16): 2944-2971.
5.	Kaur M, Singh D. Neutrophil chemotaxis caused by chronic obstructive pulmonary disease alveolar macrophages: the role of CXCL8 and the receptors CXCR1/CXCR2. J Pharmacol Exp Ther, 2013, 347(1): 173-180.
6.	Zhang J, Bai C. The significance of serum interleukin-8 in acute exacerbations of chronic obstructive pulmonary disease. Tanaffos, 2018, 17(1): 13-21.
7.	Damiá Ade D, Gimeno JC, Ferrer MJ, et al. A study of the effect of proinflammatory cytokines on the epithelial cells of smokers, with or without COPD. Arch Bronconeumol, 2011, 47(9): 447-453.
8.	丁明, 袁成, 李萍, 等. 穩定期慢性阻塞性肺疾病患者肺泡灌洗液中IL-8、IL-17水平的相關性研究. 南京醫科大學學報, 2019, 39(6): 884-889.
9.	Patel IS, Seemungal TA, Wilks M, et al. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax, 2002, 57(9): 759-764.
10.	Nakamoto K, Watanabe M, Sada M, et al. Pseudomonas aeruginosa-derived flagellin stimulates IL-6 and IL-8 production in human bronchial epithelial cells: a potential mechanism for progression and exacerbation of COPD. Exp Lung Res, 2019, 45(8): 255-266.
11.	Alcantara C, Almeida BR, Barros BCSC, et al. Histoplasma capsulatum chemotypes I and II induce IL-8 secretion in lung epithelial cells in distinct manners. Med Mycol, 2020, 58(8): 1169-1177.
12.	Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol, 2011, 89(2): 207-215.
13.	Saetta M, Mariani M, Panina-Bordignon P, et al. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2002, 165(10): 1404-1409.
14.	Costa C, Rufino R, Traves SL, et al. CXCR3 and CCR5 chemokines in induced sputum from patients with COPD. Chest, 2008, 133(1): 26-33.
15.	Freeman CM, Curtis JL, Chensue SW. CC chemokine receptor 5 and CXC chemokine receptor 6 expression by lung CD8⁺ cells correlates with chronic obstructive pulmonary disease severity. Am J Pathol, 2007, 171(3): 767-776.
16.	Costa C, Traves SL, Tudhope SJ, et al. Enhanced monocyte migration to CXCR3 and CCR5 chemokines in COPD. Eur Respir J, 2016, 47(4): 1093-1102.
17.	Vitenberga Z, Pilmane M, Babjoni?eva A. The evaluation of inflammatory, anti-inflammatory and regulatory factors contributing to the pathogenesis of COPD in airways. Pathol Res Pract, 2019, 215(1): 97-105.
18.	Sauty A, Dziejman M, Taha RA, et al. The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells. J Immunol, 1999, 162(6): 3549-3558.
19.	Clarke DL, Clifford RL, Jindarat S, et al. TNFα and IFNγ synergistically enhance transcriptional activation of CXCL10 in human airway smooth muscle cells via STAT-1, NF-κB, and the transcriptional coactivator CREB-binding protein. J Biol Chem, 2010, 285(38): 29101-29110.
20.	Grumelli S, Corry DB, Song LZ, et al. An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLoS Med, 2004, 1(1): e8.
21.	Li L, Liu Y, Chiu C, et al. A regulatory role of chemokine receptor CXCR3 in the pathogenesis of chronic obstructive pulmonary disease and emphysema. Inflammation, 2021, 44(3): 985-998.
22.	Isles HM, Herman KD, Robertson AL, et al. The CXCL12/CXCR4 signaling axis retains neutrophils at inflammatory sites in zebrafish. Front Immunol, 2019, 10: 1784.
23.	Dupin I, Allard B, Ozier A, et al. Blood fibrocytes are recruited during acute exacerbations of chronic obstructive pulmonary disease through a CXCR4-dependent pathway. J Allergy Clin Immunol, 2016, 137(4): 1036-1042.e7.
24.	Dupin I, Thumerel M, Maurat E, et al. Fibrocyte accumulation in the airway walls of COPD patients. Eur Respir J, 2019, 54(3): 1802173.
25.	李黎明, 梁利, 潘云. 穩定期慢性阻塞性肺疾病患者血清SDF-1、CXCR4表達及與肺功能和CAT評分的關系. 中國醫師雜志, 2019, 21(5): 743-745.
26.	Day C, Patel R, Guillen C, et al. The chemokine CXCL16 is highly and constitutively expressed by human bronchial epithelial cells. Exp Lung Res, 2009, 35(4): 272-283.
27.	Marques P, Collado A, Escudero P, et al. Cigarette smoke increases endothelial CXCL16-leukocyte CXCR6 adhesion in vitro and in vivo. Potential consequences in chronic obstructive pulmonary disease. Front Immunol, 2017, 8: 1766.
28.	Inui T, Watanabe M, Nakamoto K, et al. Bronchial epithelial cells produce CXCL1 in response to LPS and TNFα: a potential role in the pathogenesis of COPD. Exp Lung Res, 2018, 44(7): 323-331.
29.	Chen J, Dai L, Wang T, et al. The elevated CXCL5 levels in circulation are associated with lung function decline in COPD patients and cigarette smoking-induced mouse model of COPD. Ann Med, 2019, 51(5-6): 314-329.
30.	Di Stefano A, Caramori G, Gnemmi I, et al. Association of increased CCL5 and CXCL7 chemokine expression with neutrophil activation in severe stable COPD. Thorax, 2009, 64(11): 968-975.
31.	Mahler DA, Huang S, Tabrizi M, et al. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest, 2004, 126(3): 926-934.
32.	Rennard SI, Dale DC, Donohue JF, et al. CXCR2 antagonist MK-7123. A phase 2 proof-of-concept trial for chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2015, 191(9): 1001-1011.
33.	Lazaar AL, Miller BE, Tabberer M, et al. Effect of the CXCR2 antagonist danirixin on symptoms and health status in COPD. Eur Respir J, 2018, 52(4): 1801020.
34.	Lazaar AL, Miller BE, Donald AC, et al. CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial. Respir Res, 2020, 21(1): 149.
35.	Jing H, Liu L, Zhou J, et al. Inhibition of C-X-C motif chemokine 10 (CXCL10) protects mice from cigarette smoke-induced chronic obstructive pulmonary disease. Med Sci Monit, 2018, 24: 5748-5753.
36.	Barwinska D, Oueini H, Poirier C, et al. AMD3100 ameliorates cigarette smoke-induced emphysema-like manifestations in mice. Am J Physiol Lung Cell Mol Physiol, 2018, 315(3): L382-L386.

1. Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health study): a national cross-sectional study. Lancet, 2018, 391(10131): 1706-1717.
2. Henrot P, Prevel R, Berger P, et al. Chemokines in COPD: from implication to therapeutic Use. Int J Mol Sci, 2019, 20(11): 2785.
3. Barnes PJ. Inflammatory endotypes in COPD. Allergy, 2019, 74(7): 1249-1256.
4. Hughes CE, Nibbs RJB. A guide to chemokines and their receptors. FEBS J, 2018, 285(16): 2944-2971.
5. Kaur M, Singh D. Neutrophil chemotaxis caused by chronic obstructive pulmonary disease alveolar macrophages: the role of CXCL8 and the receptors CXCR1/CXCR2. J Pharmacol Exp Ther, 2013, 347(1): 173-180.
6. Zhang J, Bai C. The significance of serum interleukin-8 in acute exacerbations of chronic obstructive pulmonary disease. Tanaffos, 2018, 17(1): 13-21.
7. Damiá Ade D, Gimeno JC, Ferrer MJ, et al. A study of the effect of proinflammatory cytokines on the epithelial cells of smokers, with or without COPD. Arch Bronconeumol, 2011, 47(9): 447-453.
8. 丁明, 袁成, 李萍, 等. 穩定期慢性阻塞性肺疾病患者肺泡灌洗液中IL-8、IL-17水平的相關性研究. 南京醫科大學學報, 2019, 39(6): 884-889.
9. Patel IS, Seemungal TA, Wilks M, et al. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax, 2002, 57(9): 759-764.
10. Nakamoto K, Watanabe M, Sada M, et al. Pseudomonas aeruginosa-derived flagellin stimulates IL-6 and IL-8 production in human bronchial epithelial cells: a potential mechanism for progression and exacerbation of COPD. Exp Lung Res, 2019, 45(8): 255-266.
11. Alcantara C, Almeida BR, Barros BCSC, et al. Histoplasma capsulatum chemotypes I and II induce IL-8 secretion in lung epithelial cells in distinct manners. Med Mycol, 2020, 58(8): 1169-1177.
12. Groom JR, Luster AD. CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol, 2011, 89(2): 207-215.
13. Saetta M, Mariani M, Panina-Bordignon P, et al. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2002, 165(10): 1404-1409.
14. Costa C, Rufino R, Traves SL, et al. CXCR3 and CCR5 chemokines in induced sputum from patients with COPD. Chest, 2008, 133(1): 26-33.
15. Freeman CM, Curtis JL, Chensue SW. CC chemokine receptor 5 and CXC chemokine receptor 6 expression by lung CD8⁺ cells correlates with chronic obstructive pulmonary disease severity. Am J Pathol, 2007, 171(3): 767-776.
16. Costa C, Traves SL, Tudhope SJ, et al. Enhanced monocyte migration to CXCR3 and CCR5 chemokines in COPD. Eur Respir J, 2016, 47(4): 1093-1102.
17. Vitenberga Z, Pilmane M, Babjoni?eva A. The evaluation of inflammatory, anti-inflammatory and regulatory factors contributing to the pathogenesis of COPD in airways. Pathol Res Pract, 2019, 215(1): 97-105.
18. Sauty A, Dziejman M, Taha RA, et al. The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells. J Immunol, 1999, 162(6): 3549-3558.
19. Clarke DL, Clifford RL, Jindarat S, et al. TNFα and IFNγ synergistically enhance transcriptional activation of CXCL10 in human airway smooth muscle cells via STAT-1, NF-κB, and the transcriptional coactivator CREB-binding protein. J Biol Chem, 2010, 285(38): 29101-29110.
20. Grumelli S, Corry DB, Song LZ, et al. An immune basis for lung parenchymal destruction in chronic obstructive pulmonary disease and emphysema. PLoS Med, 2004, 1(1): e8.
21. Li L, Liu Y, Chiu C, et al. A regulatory role of chemokine receptor CXCR3 in the pathogenesis of chronic obstructive pulmonary disease and emphysema. Inflammation, 2021, 44(3): 985-998.
22. Isles HM, Herman KD, Robertson AL, et al. The CXCL12/CXCR4 signaling axis retains neutrophils at inflammatory sites in zebrafish. Front Immunol, 2019, 10: 1784.
23. Dupin I, Allard B, Ozier A, et al. Blood fibrocytes are recruited during acute exacerbations of chronic obstructive pulmonary disease through a CXCR4-dependent pathway. J Allergy Clin Immunol, 2016, 137(4): 1036-1042.e7.
24. Dupin I, Thumerel M, Maurat E, et al. Fibrocyte accumulation in the airway walls of COPD patients. Eur Respir J, 2019, 54(3): 1802173.
25. 李黎明, 梁利, 潘云. 穩定期慢性阻塞性肺疾病患者血清SDF-1、CXCR4表達及與肺功能和CAT評分的關系. 中國醫師雜志, 2019, 21(5): 743-745.
26. Day C, Patel R, Guillen C, et al. The chemokine CXCL16 is highly and constitutively expressed by human bronchial epithelial cells. Exp Lung Res, 2009, 35(4): 272-283.
27. Marques P, Collado A, Escudero P, et al. Cigarette smoke increases endothelial CXCL16-leukocyte CXCR6 adhesion in vitro and in vivo. Potential consequences in chronic obstructive pulmonary disease. Front Immunol, 2017, 8: 1766.
28. Inui T, Watanabe M, Nakamoto K, et al. Bronchial epithelial cells produce CXCL1 in response to LPS and TNFα: a potential role in the pathogenesis of COPD. Exp Lung Res, 2018, 44(7): 323-331.
29. Chen J, Dai L, Wang T, et al. The elevated CXCL5 levels in circulation are associated with lung function decline in COPD patients and cigarette smoking-induced mouse model of COPD. Ann Med, 2019, 51(5-6): 314-329.
30. Di Stefano A, Caramori G, Gnemmi I, et al. Association of increased CCL5 and CXCL7 chemokine expression with neutrophil activation in severe stable COPD. Thorax, 2009, 64(11): 968-975.
31. Mahler DA, Huang S, Tabrizi M, et al. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest, 2004, 126(3): 926-934.
32. Rennard SI, Dale DC, Donohue JF, et al. CXCR2 antagonist MK-7123. A phase 2 proof-of-concept trial for chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2015, 191(9): 1001-1011.
33. Lazaar AL, Miller BE, Tabberer M, et al. Effect of the CXCR2 antagonist danirixin on symptoms and health status in COPD. Eur Respir J, 2018, 52(4): 1801020.
34. Lazaar AL, Miller BE, Donald AC, et al. CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial. Respir Res, 2020, 21(1): 149.
35. Jing H, Liu L, Zhou J, et al. Inhibition of C-X-C motif chemokine 10 (CXCL10) protects mice from cigarette smoke-induced chronic obstructive pulmonary disease. Med Sci Monit, 2018, 24: 5748-5753.
36. Barwinska D, Oueini H, Poirier C, et al. AMD3100 ameliorates cigarette smoke-induced emphysema-like manifestations in mice. Am J Physiol Lung Cell Mol Physiol, 2018, 315(3): L382-L386.

Previous Article
以咯血為首發表現的肺動脈受累大動脈炎二例
Next Article
免疫檢查點抑制劑導致免疫相關性肺炎

Chinese Journal of Respiratory and Critical Care Medicine

CXC型趨化因子及其受體軸在慢性阻塞性肺疾病中的研究進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content